By Fineline Cube 
China-based Sino Biopharmaceutical Ltd (HKG: 1177) and JD Healthcare, a unit of China’s e-commerce giant JD.com (NASDAQ: JD), have established a comprehensive strategic partnership. The collaboration focuses on full-category supply chain integration, omnichannel retail solutions, and innovative marketing models.
Generic Drug Launches
As part of the partnership, Sino Bio has launched generic versions of two Japanese drugs: Loxonin (loxoprofen) from Daiichi Sankyo and Amiaid (tulobuterol) from Nitto Denko Corporation.
Partnership Scope
The collaboration covers multiple therapeutic areas, including oncology, rheumatism, surgery/analgesia, liver disease, respiratory, cardiovascular, and endocrinology. The partnership aims to expand further in these areas.
Leveraging JD Internet Hospital Resources
The two companies will utilize the high-quality doctor resources from JD Internet Hospital. They will leverage the expertise of specialists from top-tier hospitals and employ various content formats such as short videos, science communication, and thematic articles to transform authoritative medical knowledge into accessible content. This initiative will cover the entire health scene cycle, from common disease prevention to chronic disease management.-Fineline Info & Tech